

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5486084

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
Name		Execution Date
GILEAD SCIENCES, INC.		03/28/2019
RECEIVING PARTY DATA		
Name:	GILEAD PHARMASSET LLC	
Street Address:	333 LAKESIDE DRIVE	
City:	FOSTER CITY	
State/Country:	CALIFORNIA	
Postal Code:	94404	
PROPERTY NUMBERS Total: 16		
Property Type	Number	
Application Number:	61667806	
Application Number:	61798524	
Application Number:	13934090	
Application Number:	14412331	
Application Number:	14996961	
Application Number:	15185273	
Application Number:	15488035	
Application Number:	16005111	
Application Number:	61920427	
Application Number:	14575966	
Application Number:	15387318	
Application Number:	14576143	
Application Number:	61920446	
Application Number:	15611603	
Application Number:	16306424	
Application Number:	62344904	
CORRESPONDENCE DATA		
Fax Number:	(650)815-2601	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		

PATENT

Phone: 6508152600
Email: ccarter@sheppardmullin.com
Correspondent Name: SHEPPARD MULLIN RICHTER & HAMPTON LLP
Address Line 1: 379 LYTTON AVENUE
Address Line 2: LORNA L. TANNER
Address Line 4: PALO ALTO, CALIFORNIA 94301

ATTORNEY DOCKET NUMBER:	37JD-VOX
--------------------------------	----------

NAME OF SUBMITTER:	LORNA L. TANNER
---------------------------	-----------------

SIGNATURE:	/Lorna L. Tanner/
-------------------	-------------------

DATE SIGNED:	04/22/2019
---------------------	------------

Total Attachments: 13

source=913 1061 1063 1123 2019-03-29 Vox Confirmatory Assignment - Signed Notarized#page1.tif
source=913 1061 1063 1123 2019-03-29 Vox Confirmatory Assignment - Signed Notarized#page2.tif
source=913 1061 1063 1123 2019-03-29 Vox Confirmatory Assignment - Signed Notarized#page3.tif
source=913 1061 1063 1123 2019-03-29 Vox Confirmatory Assignment - Signed Notarized#page4.tif
source=913 1061 1063 1123 2019-03-29 Vox Confirmatory Assignment - Signed Notarized#page5.tif
source=913 1061 1063 1123 2019-03-29 Vox Confirmatory Assignment - Signed Notarized#page6.tif
source=913 1061 1063 1123 2019-03-29 Vox Confirmatory Assignment - Signed Notarized#page7.tif
source=913 1061 1063 1123 2019-03-29 Vox Confirmatory Assignment - Signed Notarized#page8.tif
source=913 1061 1063 1123 2019-03-29 Vox Confirmatory Assignment - Signed Notarized#page9.tif
source=913 1061 1063 1123 2019-03-29 Vox Confirmatory Assignment - Signed Notarized#page10.tif
source=913 1061 1063 1123 2019-03-29 Vox Confirmatory Assignment - Signed Notarized#page11.tif
source=913 1061 1063 1123 2019-03-29 Vox Confirmatory Assignment - Signed Notarized#page12.tif
source=913 1061 1063 1123 2019-03-29 Vox Confirmatory Assignment - Signed Notarized#page13.tif

ASSIGNMENT

This ASSIGNMENT is made BETWEEN Gilead Sciences, Inc., of 333 Lakeside Drive, Foster City, California 94404, (hereinafter "Assignor") and Gilead Pharmasset LLC, a Limited Liability Company organized under and pursuant to the laws of Delaware having its principal place of business at 333 Lakeside Drive, Foster City, California 94404, (hereinafter referred to singly and collectively as "Assignee").

WHEREAS


A) The ASSIGNOR was the legal owner of the Patents or Patent Applications, as well as the inventions set forth therein, in the United States and all foreign countries, listed in Exhibit A.

B) The ASSIGNEE was desirous of acquiring the full and exclusive right, title and interest in and to said Patents or Patent Applications, as well as the inventions set forth therein, in the United States and all foreign countries, listed in Exhibit A.

IT IS HEREBY CONFIRMED that the ASSIGNOR assigned to the ASSIGNEE all its right, title and interest in and to said inventions for U.S. and all foreign countries, and in and to said Patents and Patent Applications listed in Exhibit A, including any and all priority applications, divisional, continuation, continuation-in-part, reissue or extensions thereof, to be held and enjoyed by Assignee for its own use as fully and entirely as the same would have been held and enjoyed by Assignor had this assignment not been made, by virtue of an agreement between ASSIGNOR and ASSIGNEE dated as of December 1, 2016 (the "GS-9857 Assignment Agreement"). This ASSIGNMENT is merely confirmatory and made pursuant to the GS-9857 Assignment Agreement.

[Signature Pages Follow]

Executed this 28 day of March, 2019.



Signature

J. Elin Hartrum
Name

Vice President, Patents
Title
for
GILEAD SCIENCES, INC.
333 Lakeside Drive
Foster City, California 94404
(ASSIGNOR)

Executed this 28 day of March, 2019.



Signature

J. Elin Hartrum
Name

Vice President, Patents
Title
for
GILEAD PHARMASSET LLC
333 Lakeside Drive
Foster City, California 94404
(ASSIGNEE)

EXHIBIT A

Docket No.	Ref. No.	Appl. No.	Patent No.	Title	Country
37JD-192656-AP	913.P2AP	AP/P/2014/008166	AP 3903	INHIBITORS OF HEPATITIS C VIRUS	AP
37JD-192656-AR	913.P2AR	20130102368		INHIBITORS OF FLAVIVIRIDAE VIRUSES	AR
37JD-192656-AU	913.P2AUD2	2013286729	2013286729	INHIBITORS OF HEPATITIS C VIRUS	AU
37JD-192656-AU2	913.P2AUD	2016200201		INHIBITORS OF HEPATITIS C VIRUS	AU
37JD-192656-AU3	913.P2AUD2	2016200670		INHIBITORS OF HEPATITIS C VIRUS	AU
37JD-192656-AU4	913.P2AUD1D	2017203984		INHIBITORS OF HEPATITIS C VIRUS	AU
37JD-192656-BO	913.P2BO	SP-00204-2013		INHIBITORS OF HEPATITIS C VIRUS	BO
37JD-192656-BO2	913.P2BOD	SP-00204-2013-F1		INHIBITORS OF HEPATITIS C VIRUS	BO
37JD-192656-BR	913.P2BR	BR112014033080-8		INHIBITORS OF HEPATITIS C VIRUS	BR
37JD-192656-BS	913.P2BS	2538		INHIBITORS OF HEPATITIS C VIRUS	BS
37JD-192656-CA	913.P2CA	2877005	2877005	INHIBITORS OF HEPATITIS C VIRUS	CA
37JD-192656-CL	913.P2CL	3634-2014		INHIBITORS OF HEPATITIS C VIRUS	CL
37JD-192656-CN	913.P2CN	201380042756.6	ZL 201380042756.6	INHIBITORS OF HEPATITIS C VIRUS	CN
37JD-192656-CN2	913.P2CND	201610474633.5		INHIBITORS OF HEPATITIS C VIRUS	CN
37JD-192656-CO	913.P2CO	15-005.727	6755	INHIBITORS OF HEPATITIS C VIRUS	CO
37JD-192656-CR	913.P2CR	2015-0045		INHIBITORS OF HEPATITIS C VIRUS	CR
37JD-192656-EA	913.P2EA	201492214	0027390	INHIBITORS OF HEPATITIS C VIRUS	EA
37JD-192656-EA2	913.P2EAD	201790661		INHIBITORS OF HEPATITIS C VIRUS	EA
37JD-192656-EC	913.P2EC	2015-2066		INHIBITORS OF HEPATITIS C VIRUS	EC
37JD-192656-EG	913.P2EG	2100/2014 PCT		INHIBITORS OF HEPATITIS C VIRUS	EG
37JD-192656-EP	913.P2GR	13739324.5	2870160	INHIBITORS OF HEPATITIS C VIRUS	GR

Docket No.	Ref. No.	Appl. No.	Patent No.	Title	Country
37JD-192656-EP	913.P2SK	13739324.5	2870160	INHIBITORS OF HEPATITIS C VIRUS	SK
37JD-192656-EP	913.P2IT	13739324.5	502016000128483	INHIBITORS OF HEPATITIS C VIRUS	IT
37JD-192656-EP	913.P2RS	13739324.5	P-2016/1182	INHIBITORS OF HEPATITIS C VIRUS	RS
37JD-192656-EP	913.P2EPLV	13739324.5	2870160	INHIBITORS OF HEPATITIS C VIRUS	LV
37JD-192656-EP	913.P2AT	13739324.5	AT-E 0 832 639	INHIBITORS OF HEPATITIS C VIRUS	AT
37JD-192656-EP	913.P2FI	13739324.5	2870160	INHIBITORS OF HEPATITIS C VIRUS	FI
37JD-192656-EP	913.P2PL	13739324.5	2870160	INHIBITORS OF HEPATITIS C VIRUS	PL
37JD-192656-EP	913.P2DK	13739324.5	2870160	INHIBITORS OF HEPATITIS C VIRUS	DK
37JD-192656-EP	913.P2CY	13739324.5	CY1118379	INHIBITORS OF HEPATITIS C VIRUS	CY
37JD-192656-EP	913.P2AL	13739324.5	6120	INHIBITORS OF HEPATITIS C VIRUS	AL
37JD-192656-EP	913.P2IS	13739324.5	2870160	INHIBITORS OF HEPATITIS C VIRUS	IS
37JD-192656-EP	913.P2ME	13739324.5	P-2016/245	INHIBITORS OF HEPATITIS C VIRUS	ME
37JD-192656-EP	913.P2BE	13739324.5	2870160	INHIBITORS OF HEPATITIS C VIRUS	BE
37JD-192656-EP	913.P2TR	13739324.5	2016/19079	INHIBITORS OF HEPATITIS C VIRUS	TR
37JD-192656-EP	913.P2LU	13739324.5	2870160	INHIBITORS OF HEPATITIS C VIRUS	LU
37JD-192656-EP	913.P2EP	13739324.5	2870160	INHIBITORS OF HEPATITIS C VIRUS	EP
37JD-192656-EP	913.P2GB	13739324.5	2870160	INHIBITORS OF HEPATITIS C VIRUS	GB
37JD-192656-EP	913.P2RO	13739324.5	2870160	INHIBITORS OF HEPATITIS C VIRUS	RO
37JD-192656-EP	913.P2ES	13739324.5	2870160	INHIBITORS OF HEPATITIS C VIRUS	ES
37JD-192656-EP	913.P2HU	13739324.5	2870160	INHIBITORS OF HEPATITIS C VIRUS	HU
37JD-192656-EP	913.P2SI	13739324.5	P-201330345	INHIBITORS OF HEPATITIS C VIRUS	SI
37JD-192656-EP	913.P2BA	13739324.5	E 02180	INHIBITORS OF HEPATITIS C VIRUS	BA

Docket No.	Ref. No.	Appl. No.	Patent No.	Title	Country
37JD-192656-EP	913.P2MT	13739324.5	2870160	INHIBITORS OF HEPATITIS C VIRUS	MT
37JD-192656-EP	913.P2CH	13739324.5	2870160	INHIBITORS OF HEPATITIS C VIRUS	CH
37JD-192656-EP	913.P2MC	13739324.5	2870160	INHIBITORS OF HEPATITIS C VIRUS	MC
37JD-192656-EP	913.P2NO	13739324.5	2870160	INHIBITORS OF HEPATITIS C VIRUS	NO
37JD-192656-EP	913.P2DE	13739324.5	60 2013 012 186.9	INHIBITORS OF HEPATITIS C VIRUS	DE
37JD-192656-EP	913.P2SE	13739324.5	2870160	INHIBITORS OF HEPATITIS C VIRUS	SE
37JD-192656-EP	913.P2FR	13739324.5	2870160	INHIBITORS OF HEPATITIS C VIRUS	FR
37JD-192656-EP	913.P2PT	13739324.5	2870160	INHIBITORS OF HEPATITIS C VIRUS	PT
37JD-192656-EP	913.P2SM	13739324.5	2870160	INHIBITORS OF HEPATITIS C VIRUS	SM
37JD-192656-EP	913.P2LT	13739324.5	2870160	INHIBITORS OF HEPATITIS C VIRUS	LT
37JD-192656-EP	913.P2IE	13739324.5	2870160	INHIBITORS OF HEPATITIS C VIRUS	IE
37JD-192656-EP	913.P2CZ	13739324.5	2870160	INHIBITORS OF HEPATITIS C VIRUS	CZ
37JD-192656-EP	913.P2BG	13739324.5	2870160	INHIBITORS OF HEPATITIS C VIRUS	BG
37JD-192656-EP	913.P2MK	13739324.5	2870160	INHIBITORS OF HEPATITIS C VIRUS	MK
37JD-192656-EP	913.P2HR	13739324.5	P20161379T	INHIBITORS OF HEPATITIS C VIRUS	HR
37JD-192656-EP	913.P2EE	13739324.5	2870160	INHIBITORS OF HEPATITIS C VIRUS	EE
37JD-192656-EP	913.P2NL	13739324.5	2870160	INHIBITORS OF HEPATITIS C VIRUS	NL
37JD-192656-EP2	913.P2EPD	16190694.6	3159345	INHIBITORS OF HEPATITIS C VIRUS	EP
37JD-192656-EP3	913.P2EPD2	18215386.6		INHIBITORS OF HEPATITIS C VIRUS	EP
37JD-192656-GC	913.P2GC	2013/24849		INHIBITORS OF HEPATITIS C VIRUS	GC
37JD-192656-HKCN	913.P2CNHK	15109972.6	1209416B	INHIBITORS OF HEPATITIS C VIRUS	HK
37JD-192656-HKCN2	913.P2CNDHK	17104865.5		INHIBITORS OF HEPATITIS C VIRUS	HK

Docket No.	Ref. No.	Appl. No.	Patent No.	Title	Country
37JD-192656-HKEP	913.P2EPHK	15110878.9		INHIBITORS OF HEPATITIS C VIRUS	HK
37JD-192656-HKEP2	913.P2EPDHK	17110191.7		INHIBITORS OF HEPATITIS C VIRUS	HK
37JD-192656-ID	913.P2ID	P00 2014 08047		INHIBITORS OF HEPATITIS C VIRUS	ID
37JD-192656-IL	913.P2IL	236500	236500	INHIBITORS OF HEPATITIS C VIRUS	IL
37JD-192656-IL2	913.P2ILD	252446	252446	MACROCYCLIC COMPOUNDS COMPRISING QUINOXALINE AND THE PROCESS FOR THEIR PREPARATION	IL
37JD-192656-IL3	913.P2ILD2	261581		INHIBITORS OF HEPATITIS C VIRUS	IL
37JD-192656-IN	913.P2IN	2598/MUMNP/2014		INHIBITORS OF HEPATITIS C VIRUS	IN
37JD-192656-JP	913.P2JP	2015-520657	6025977	INHIBITORS OF HEPATITIS C VIRUS	JP
37JD-192656-JP2	913.P2JPD	2015-220577		INHIBITORS OF HEPATITIS C VIRUS	JP
37JD-192656-JP3	913.P2JPD2	2018-111786		INHIBITORS OF HEPATITIS C VIRUS	JP
37JD-192656-KR	913.KR	10-2014-7037149	10-1610575	INHIBITORS OF HEPATITIS C VIRUS	KR
37JD-192656-KR2	913.P2KRD	10-2016-7008636		INHIBITORS OF HEPATITIS C VIRUS	KR
37JD-192656-MA	913.P2MA	37659	37659	INHIBITORS OF HEPATITIS C VIRUS	MA
37JD-192656-MD	913.P2MD	a20140136		INHIBITORS OF HEPATITIS C VIRUS	MD
37JD-192656-MD2	913.P2MDD	a 2018 0040		INHIBITORS OF HEPATITIS C VIRUS	MD
37JD-192656-MO	913.P2CN-MO	J/002413	J/002413	INHIBITORS OF HEPATITIS C VIRUS	MO
37JD-192656-MX	913.P2MX	MX/a/2014/015846	360597	INHIBITORS OF HEPATITIS C VIRUS	MX
37JD-192656-MX2	913.P2MXD	MX/a/2018/013668		INHIBITORS OF HEPATITIS C VIRUS	MX
37JD-192656-MY	913.P2MY	PI 2014003617		INHIBITORS OF HEPATITIS C VIRUS	MY
37JD-192656-MY2	913.P2MYD	PI2018702791		INHIBITORS OF HEPATITIS C VIRUS	MY
37JD-192656-NZ	913.P2NZ	703064	703064	INHIBITORS OF HEPATITIS C VIRUS	NZ

Docket No.	Ref. No.	Appl. No.	Patent No.	Title	Country
37JD-192656-NZ2	913.P2.NZD	722908		INHIBITORS OF HEPATITIS C VIRUS	NZ
37JD-192656-NZ3	913.P2.NZD2	734890		INHIBITORS OF HEPATITIS C VIRUS	NZ
37JD-192656-NZ4	913.P2.NZD3	739248		INHIBITORS OF HEPATITIS C VIRUS	NZ
37JD-192656-OA	913.P2OA	1201400575	17196	INHIBITORS OF HEPATITIS C VIRUS	OA
37JD-192656-P	913.P	61/667806		INHIBITORS OF FLAVIVIRIDAE VIRUSES	US
37JD-192656-P2	913.P2	61/798524		INHIBITORS OF HEPATITIS C VIRUS	US
37JD-192656-PA	913.P2PA	90482		INHIBITORS OF HEPATITIS C VIRUS	PA
37JD-192656-PE	913.P2PE	2587-2014/DIN		INHIBITORS OF HEPATITIS C VIRUS	PE
37JD-192656-PH	913.P2PH	1-2014-502862	1-2014-502862	INHIBITORS OF HEPATITIS C VIRUS	PH
37JD-192656-PH2	913.P2DIV.PH	1-2016-502040		INHIBITORS OF HEPATITIS C VIRUS	PH
37JD-192656-PK	913.P2PK	442/2013		INHIBITORS OF FLAVIVIRIDAE VIRUSES	PK
37JD-192656-PY	913.P2PY	29361/2013		INHIBITORS OF HEPATITIS C VIRUS	PY
37JD-192656-SG	913.P2SG	11201408739V	11201408739V	INHIBITORS OF HEPATITIS C VIRUS	SG
37JD-192656-SG2	913.P2.SG DIV	10201702950T		INHIBITORS OF HEPATITIS C VIRUS	SG
37JD-192656-SV	913.P2SV	2015004886		INHIBITORS OF HEPATITIS C VIRUS	SV
37JD-192656-TH	913.P2TH	1401007673		INHIBITORS OF HEPATITIS C VIRUS	TH
37JD-192656-TW	913.P2TW	102123626	1602822	INHIBITORS OF HEPATITIS C VIRUS	TW
37JD-192656-UA	913.P2UA	a2014 13651		INHIBITORS OF HEPATITIS C VIRUS	UA
37JD-192656-US	913.P2C	13/934090	9296782	INHIBITORS OF HEPATITIS C VIRUS	US
37JD-192656-US2	913.P2FUS	14/412331		INHIBITORS OF HEPATITIS C VIRUS	US
37JD-192656-US3	913.P2C2	14/996961		INHIBITORS OF HEPATITIS C VIRUS	US
37JD-192656-US4	913.P2C3	15/185273	9655944	INHIBITORS OF HEPATITIS C VIRUS	US

Docket No.	Ref. No.	Appl. No.	Patent No.	Title	Country
37JD-192656-US6	913.P2C4	15/488035		INHIBITORS OF HEPATITIS C VIRUS	US
37JD-192656-US7	913.P2C5	16/005111		INHIBITORS OF HEPATITIS C VIRUS	US
37JD-192656-UY	913.P2UY	34.888		INHIBITORS OF FLAVIVIRIDAE VIRUSES	UY
37JD-192656-VE	913.P2VE	000831-2013		INHIBITORS OF FLAVIVIRIDAE VIRUSES	VE
37JD-192656-VN	913.P2VN	1-2014-04304		INHIBITORS OF HEPATITIS C VIRUS	VN
37JD-192656-WO	913.P2F	PCT/US2013/049119		INHIBITORS OF HEPATITIS C VIRUS	WO
37JD-192656-ZA	913.P2ZA	2014/09219	2014/09219	INHIBITORS OF HEPATITIS C VIRUS	ZA
37JD-192656-ZA2	913.P2ZAD	2015/07933		INHIBITORS OF HEPATITIS C VIRUS	ZA
37JD-195543-AR	1061.AR	20140104909		CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND	AR
37JD-195543-AT	1061.AT	14824322.3	3087086	CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND	AT
37JD-195543-AU	1061.AU	2014370124		CRYSTALLINE FORMS OF A MACROCYCLIC HCV NS3 INHIBITING TRIPEPTIDE	AU
37JD-195543-BE	1061.BE	14824322.3	3087086	CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND	BE
37JD-195543-BO	1061.BO	00330-2014		CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND	BO
37JD-195543-BS	1061.BS	2662	2662	CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND	BS
37JD-195543-CA	1061.CA	2934049		CRYSTALLINE FORMS OF A MACROCYCLIC HCV NS3 INHIBITING TRIPEPTIDE	CA
37JD-195543-CH	1061.CH	14824322.3	3087086	CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND	CH
37JD-195543-DE	1061.DE	14824322.3	3087086	CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND	DE
37JD-195543-EP	1061.EP	14824322.3	3087086	CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND	EP
37JD-195543-ES	1061.ES	14824322.3	3087086	CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND	ES
37JD-195543-FR	1061.FR	14824322.3	3087086	CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND	FR
37JD-195543-GB	1061.GB	14824322.3	3087086	CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND	GB

Docket No.	Ref. No.	Appl. No.	Patent No.	Title	Country
37JD-195543-GC	1061.GC	2014/28652		CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND	GC
37JD-195543-HK	1061.HK	17104001.0		CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND	HK
37JD-195543-IE	1061.IE	14824322.3	3087086	CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND	IE
37JD-195543-IT	1061.IT	14824322.3	3087086	CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND	IT
37JD-195543-JP	1061.JP	2016-560857		CRYSTALLINE FORMS OF A MACROCYCLIC HCV NS3 INHIBITING TRIPEPTIDE	JP
37JD-195543-JP2	1061.JPD	2019-20540		CRYSTALLINE FORMS OF A MACROCYCLIC HCV NS3 INHIBITING TRIPEPTIDE	JP
37JD-195543-NL	1061.NL	14824322.3	3087086	CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND	NL
37JD-195543-NZ	1061.NZ	720887		CRYSTALLINE FORMS OF A MACROCYCLIC HCV NS3 INHIBITING TRIPEPTIDE	NZ
37JD-195543-P	1061.P	61/920427		CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND	US
37JD-195543-PK	1061.PK	905/2014		CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND	PK
37JD-195543-PT	1061.PT	14824322.3	3087086	CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND	PT
37JD-195543-PY	1061.PY	04607/2014		CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND	PY
37JD-195543-TW	1061.TW	103144805		CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND	TW
37JD-195543-US	1061.PC	14/575966	9562058	CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND	US
37JD-195543-US2	1061.PCD	15/387318	9862728	CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND	US
37JD-195543-UY	1061.UY	35918		CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND	UY
37JD-195543-VE	1061.VE	001589-2014		CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND	VE
37JD-195543-WO	1061.PF	PCT/US2014/071310		CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND	WO
37JD-191696-AR	1063.AR	20140104910		SYNTHESIS OF AN ANTIVIRAL COMPOUND	AR
37JD-191696-AU	1063.AU	2014370125	2014370125	SYNTHESIS OF A MACROCYCLIC HCV NS3 INHIBITING TRIPEPTIDE	AU
37JD-191696-BR	1063.BR	BR112016014649-2		SYNTHESIS OF A MACROCYCLIC HCV NS3 INHIBITING TRIPEPTIDE	BR

Docket No.	Ref. No.	Appl. No.	Patent No.	Title	Country
37JD-191696-BS	1063.BS	2526		SYNTHESIS OF AN ANTIVIRAL COMPOUND	BS
37JD-191696-CA	1063.CA	2934537		SYNTHESIS OF A MACROCYCLIC HCV NS3 INHIBITING TRIPEPTIDE	CA
37JD-191696-CN	1063.CN	201480070017.2		SYNTHESIS OF A MACROCYCLIC HCV NS3 INHIBITING TRIPEPTIDE	CN
37JD-191696-EA	1063.EA	201691031		SYNTHESIS OF A MACROCYCLIC HCV NS3 INHIBITING TRIPEPTIDE	EA
37JD-191696-EP	1063.EP	14822040.3	3087085	SYNTHESIS OF A MACROCYCLIC HCV NS3 INHIBITING TRIPEPTIDE	EP
37JD-191696-HK	1063.HK	16110589.8		SYNTHESIS OF A MACROCYCLIC HCV NS3 INHIBITING TRIPEPTIDE	HK
37JD-191696-HK2	1063.EPHK	17104002.9		SYNTHESIS OF A MACROCYCLIC HCV NS3 INHIBITING TRIPEPTIDE	HK
37JD-191696-IL	1063.IL	246064		SYNTHESIS OF A MACROCYCLIC HCV NS3 INHIBITING TRIPEPTIDE	IL
37JD-191696-IN	1063.IN	201627021364		SYNTHESIS OF A MACROCYCLIC HCV NS3 INHIBITING TRIPEPTIDE	IN
37JD-191696-JP	1063.JP	2016-541595	6425727	A MACROCYCLIC HCV NS3 INHIBITING TRIPEPTIDE	JP
37JD-191696-KR	1063.KR	10-2016-7016776		SYNTHESIS OF A MACROCYCLIC HCV NS3 INHIBITING TRIPEPTIDE	KR
37JD-191696-MX	1063.MX	MX/a/2016/008452		SYNTHESIS OF A MACROCYCLIC HCV NS3 INHIBITING TRIPEPTIDE	MX
37JD-191696-NZ	1063.NZ	720745	720745	SYNTHESIS OF A MACROCYCLIC HCV NS3 INHIBITING TRIPEPTIDE	NZ
37JD-191696-SG	1063.SG	11201604482Q		SYNTHESIS OF A MACROCYCLIC HCV NS3 INHIBITING TRIPEPTIDE	SG
37JD-191696-TW	1063.TW	103144804		SYNTHESIS OF AN ANTIVIRAL COMPOUND	TW
37JD-191696-US	1063.PC	14/576143	9440991	SYNTHESIS OF AN ANTIVIRAL COMPOUND	US
37JD-191696-P	1063.P	61/920446		SYNTHESIS OF AN ANTIVIRAL COMPOUND	US
37JD-191696-WO	1063.PF	PCT/US2014/071319		SYNTHESIS OF AN ANTIVIRAL COMPOUND	WO
37JD-214327-AR	1123.AR	20170101445		COMBINATION FORMULATION OF THREE ANTIVIRAL COMPOUNDS	AR
37JD-214327-AU	1123.AU	2017273851		COMBINATION FORMULATION OF THREE ANTIVIRAL COMPOUNDS	AU
37JD-214327-BD	1123.BD	118-2017		COMBINATION FORMULATION OF THREE ANTIVIRAL COMPOUNDS	BD

Docket No.	Ref. No.	Appl. No.	Patent No.	Title	Country
37JD-214327-BO	1123.BO	SP-00113-2017		COMBINATION FORMULATION OF THREE ANTIVIRAL COMPOUNDS	BO
37JD-214327-BR	1123.BR	BR102017011025-7		COMBINATION FORMULATION OF THREE ANTIVIRAL COMPOUNDS	BR
37JD-214327-BS	1123.BS	2793		COMBINATION FORMULATION OF THREE ANTIVIRAL COMPOUNDS	BS
37JD-214327-CA	1123.CA	3025380		COMBINATION FORMULATION OF THREE ANTIVIRAL COMPOUNDS	CA
37JD-214327-CN	1123.CN	201780034117.3		COMBINATION FORMULATION OF THREE ANTIVIRAL COMPOUNDS	CN
37JD-214327-EA	1123.EA	201892376		COMBINATION FORMULATION OF THREE ANTIVIRAL COMPOUNDS	EA
37JD-214327-EP	1123.EP	17729702.5		COMBINATION FORMULATION OF THREE ANTIVIRAL COMPOUNDS	EP
37JD-214327-GC	1123.GC	33457		COMBINATION FORMULATION OF THREE ANTIVIRAL COMPOUNDS	GC
37JD-214327-IL	1123.IL	263155		COMBINATION FORMULATION OF THREE ANTIVIRAL COMPOUNDS	IL
37JD-214327-IN	1123.IN	201817049048		COMBINATION FORMULATION OF THREE ANTIVIRAL COMPOUNDS	IN
37JD-214327-JO	1123.JO	127/2017		COMBINATION FORMULATION OF THREE ANTIVIRAL COMPOUNDS	JO
37JD-214327-JP	1123.JP	2018-562617		COMBINATION FORMULATION OF THREE ANTIVIRAL COMPOUNDS	JP
37JD-214327-KR	1123.KR	10-2018-7037767		COMBINATION FORMULATION OF THREE ANTIVIRAL COMPOUNDS	KR
37JD-214327-MX	1123.MX	MX/a/2018/014790		COMBINATION FORMULATION OF THREE ANTIVIRAL COMPOUNDS	MX
37JD-214327-NZ	1123.NZ	748452		COMBINATION FORMULATION OF THREE ANTIVIRAL COMPOUNDS	NZ

Docket No.	Ref. No.	Appl. No.	Patent No.	Title	Country
37JD-214327-PK	1123.PK	306/2017		COMBINATION FORMULATION OF THREE ANTIVIRAL COMPOUNDS	PK
37JD-214327-PY	1123.PY	1732693		COMBINATION FORMULATION OF THREE ANTIVIRAL COMPOUNDS	PY
37JD-214327-SG	1123.SG	11201810189S		COMBINATION FORMULATION OF THREE ANTIVIRAL COMPOUNDS	SG
37JD-214327-TW	1123.TW	106117756		COMBINATION FORMULATION OF THREE ANTIVIRAL COMPOUNDS	TW
37JD-214327-US	1123.US	15/611603		COMBINATION FORMULATION OF THREE ANTIVIRAL COMPOUNDS	US
37JD-214327-US2	1123.PFUS	16/306424		COMBINATION FORMULATION OF THREE ANTIVIRAL COMPOUNDS	US
37JD-214327-P	1123.P	62/344904		COMBINATION FORMULATION OF THREE ANTIVIRAL COMPOUNDS	US
37JD-214327-UY	1123.U	37.261		COMBINATION FORMULATION OF THREE ANTIVIRAL COMPOUNDS	UY
37JD-214327-VE	1123.VE	000225-2017		COMBINATION FORMULATION OF THREE ANTIVIRAL COMPOUNDS	VE
37JD-214327-WO	1123.WO	PCT/US2017/035539		COMBINATION FORMULATION OF THREE ANTIVIRAL COMPOUNDS	WO

ACKNOWLEDGMENT

A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document.


State of California
County of San Mateo)

On March 28, 2019 before me, David Castro, Notary Public
(insert name and title of the officer)

personally appeared J. Elin Hartrum
who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Signature  (Seal)

